$-0.05
(Market cap
$590 Mln
Recently Viewed
Clear AllMarket cap
$590 Mln
Revenue (TTM)
$4 Mln
P/E Ratio
--
P/B Ratio
149.2
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-7.8 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-2
Debt to Equity
-2.7
Book Value
$--
EPS
$-0.2
Face value
--
Shares outstanding
327,897,296
CFO
$-314.65 Mln
EBITDA
$-422.89 Mln
Net Profit
$-349.21 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Ocugen (OCGN)
| 41.1 | -23.2 | 17.6 | 172.6 | 33.5 | -20.9 | -35.0 |
|
BSE Sensex
| -7.9 | 4.6 | -6.5 | 1.6 | 8.9 | 9.8 | 11.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Ocugen (OCGN)
| 67.7 | 39.6 | -55.8 | -71.4 | 148.6 | 251.9 | -90.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Ocugen (OCGN)
|
1.9 | 590.2 | 4.4 | -67.9 | -1,425.7 | -776.9 | -- | 149.2 |
| 67.6 | 9,338.8 | 1,091.0 | 202.3 | 31.6 | 31.3 | 41.7 | 15.7 | |
| 241.1 | 15,338.5 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 78.1 | |
| 64.2 | 8,171.9 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 44.2 | 12,295.6 | 2,320.1 | 782.6 | 39.0 | 35.5 | 16.5 | 5.4 | |
| 85.3 | 11,333.1 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 519.9 | 12,043.3 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 20.0 | |
| 526.1 | 14,850.2 | 2,530.2 | 451.1 | 21.3 | 70.2 | 34 | 32.3 | |
| 102.7 | 8,256.4 | 0.0 | -425.4 | -- | -36.7 | -- | 6.6 | |
| 316.9 | 9,569.6 | 0.0 | -303.3 | -- | -45.8 | -- | 10.9 |
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene... therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania. Address: 11 Great Valley Parkway, Malvern, PA, United States, 19355 Read more
Co-Founder, CEO & Chairman
Dr. Shankar Musunuri M.B.A., Ph.D.
Co-Founder, CEO & Chairman
Dr. Shankar Musunuri M.B.A., Ph.D.
Headquarters
Malvern, PA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Ocugen Inc (OCGN) is $1.91 (NASDAQ) as of 16-Apr-2026 12:38 EDT. Ocugen Inc (OCGN) has given a return of 33.53% in the last 3 years.
Since, TTM earnings of Ocugen Inc (OCGN) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-5.97
|
-33.29
|
|
2024
|
-4.04
|
7.36
|
|
2023
|
-2.22
|
3.46
|
|
2022
|
-3.59
|
3.78
|
|
2021
|
-15.20
|
9.26
|
The 52-week high and low of Ocugen Inc (OCGN) are Rs 2.72 and Rs 0.64 as of 17-Apr-2026.
Ocugen Inc (OCGN) has a market capitalisation of $ 590 Mln as on 15-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Ocugen Inc (OCGN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.